Best of ASCO - 2014 Annual Meeting

 

Welcome

Pancreatic Cancer

Gastrointestinal (Noncolorectal) Cancer

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A phase I/II study of GSK3145095 alone and in combination with anticancer agents including pembrolizumab in adults with selected solid tumors.

Deirdre Jill Cohen

TPS4165

A phase Ib dose-escalation and cohort-expansion study of safety and activity of the transforming growth factor (TGF) β receptor I kinase inhibitor galunisertib plus the anti-PD-L1 antibody durvalumab in metastatic pancreatic cancer.

Davide Melisi

4124

A randomized noncomparative phase II study of maintenance therapy with multiepitope vaccine Tedopi (OSE2101) ± nivolumab or FOLFIRI after induction chemotherapy (CT) with FOLFIRINOX in patients (Pts) with advanced pancreatic ductal adenocarcinoma (aPDAC) (TEDOPaM–PRODIGE 63 GERCOR D17-01 study).

Cindy Neuzillet

TPS4160

A randomized phase II trial of niraparib plus either nivolumab or ipilimumab in patients with advanced pancreatic cancer whose cancer has not progressed on platinum-based therapy.

Kim Anna Reiss

TPS4161

A randomized, phase II clinical trial of preoperative stereotactic body radiation therapy versus conventionally fractionated chemoradiation for resectable, borderline-resectable, or locally advanced type a pancreatic adenocarcinoma.

William Adrian Hall

TPS4167

A retrospective analysis of antibiotics usage and effect on overall survival and progressive free survival in patients with metastatic pancreatic cancer.

Chirayu Mohindroo

e15781

Adaptive Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4419 in pancreatic cancer.

Jon Holmlund

TPS4164

Adjuvant FOLFOX + nab-paclitaxel (FOLFOX-A)for pancreatic cancer, BrUOG 278: A Brown University oncology research group phase II study.

Howard Safran

e15733

Adjuvant nab-paclitaxel plus gemcitabine versus gemcitabine in resected pancreatic ductal adenocarcinoma: A Chinese single institution.

Zhuzeng Yin

e15740

Adjuvant therapy with gemcitabine and stereotactic body radiation therapy versus gemcitabine alone for resected stage II pancreatic cancer: A prospective, randomized, open label, single-center trial.

Tao Ma

e15765

Alpha-1-acid glycoprotein 1 (AGP1) as a novel biomarker for pancreatic cancer.

Qimin Zhou

e15708

APACT: phase III, multicenter, international, open-label, randomized trial of adjuvant nab-paclitaxel plus gemcitabine (nab-P/G) vs gemcitabine (G) for surgically resected pancreatic adenocarcinoma.

Margaret A. Tempero

4000

Association of BRCA-mutant pancreatic cancer with high tumor mutational burden (TMB) and higher PD-L1 expression.

Andreas Seeber

4133

Association of pancreatic cancer stem cells with tumor stroma type.

Ibrahim Halil Sahin

e15771

Cellular heterogeneity during mouse pancreatic ductal adenocarcinoma progression at single-cell resolution.

Abdel Nasser Hosein

e15739

Change in body composition and survival in patients with pancreatic cancer.

Mridula Krishnan

e15716

Clinical and immune responses using anti-CD3 x anti-EGFR bispecific antibody armed T cells (BATs) for locally advanced or metastatic pancreatic cancer.

Lawrence G. Lum

4135

Combination therapy of dendritic cell vaccination plus chemotherapy in pancreatic cancer.

Maurizio Chiriva-Internati

e15748

Comparison of FOLFIRINOX and gemcitabine with nab-paclitaxel in metastatic pancreatic cancer: Using Korean Pancreatic Cancer (K-PaC) Registry.

Jong-Chan Lee

e15762

Comparison of the mutation profile between pancreatic head/neck and body/tail cancers.

Junliang Lu

e15752

Comprehensive genomic analysis of metastatic pancreatic ductal adenocarcinoma (mPDAC) reveals a significant proportion of clinical actionable aberrations.

Michael Lee

e15753

Copy number instability (CNI) combined with CA19-9 as a biomarker for postoperative prognostic prediction of pancreatic cancer.

Qian Zhan

e15730

Defining the heterogeneity landscape of pancreatic cancer copy number alterations.

Timour Baslan

e15776

Development of a radiomics nomogram based on the CE-CT features to predict the survival of upfront resectable patients with pancreatic head cancer and suspected venous invasion.

Yinan Shen

e15760

DNA repair deficiency association with prognosis in pancreatic cancer: A single-institution experience.

Suhaib Bajwa

e15798

Dynamic assessment of circulating tumor DNA in prediction of response to nab-paclitaxel-based first-line chemotherapy in metastatic pancreatic cancer.

Yan Shi

e15769

Effect of ARK5 on the anti-tumour activity of OSI-027 via regulation of epithelial-mesenchymal transition in pancreatic cancer.

Xiao Zhi

e15758

Effect of irreversible electroporation (IRE) combined with chemotherapy (C) on survival in locally advanced pancreatic cancer (LAPC) patients (pts).

Michalis Karamouzis

e15723

Effect of LAT2 on glutamine-dependent mTOR activation to promote glycolysis and chemoresistance in pancreatic cancer.

Jiangdong Qiu

e15759

Effect of neoadjuvant chemotherapy using gemcitabine and S1 before surgery for pancreatic cancer on quality of life.

Naoko Sato

e15719

Effect of neoantigen reactive T cells combined with chemotherapy and radiation on survival in advanced pancreatic cancer.

Qin Liu

e15756

Effect of targeting CD40 for DC vaccination in pancreatic adenocarcinoma.

Sai Ping Lau

e15783

Effect of tumor cell-derived debris and IgG on metastasis of pancreatic cancer and inflammation through tumor-associated macrophages.

Qi Zhang

e15764

Efficacy and safety of FOLFIRINOX in elderly patients with advanced pancreatic adenocarcinoma.

Jae Hyup Jung

e15729

Efficacy and tolerability of adjuvant gemcitabine and capecitabine in patients with resected pancreatic cancer in US population: A single network experience.

Gurveen Kaur

e15789

Elevated pretreatment serum IL-8 and PD-L1 and overall survival in a phase III randomized advanced pancreatic cancer clinical trial.

Ashok Maddukuri

4131

Epidemiology, national trends and clinical associations of pancreatic adenocarcinoma in chronic pancreatitis patients: A nationwide inpatient sample (NIS) study.

Ahmed Elkafrawy

e15737

Exploiting DNA repair alterations in metastatic pancreatic cancer (mPAC): Is MGMT methylation a new therapeutic target?

Monica Niger

e15770

Exposure-response (E-R) analysis of efficacy of pegvorhyaluronidase alfa (PEGPH20) in combination with nab-paclitaxel + gemcitabine (AG) in patients (Pts) with metastatic pancreatic ductal adenocarcinoma.

Yong Liu

e15746

Expression level of NRP1 and SMAD2 in correlation to mutational status of RAS (BRAF) in pancreatic cancer.

Libor Stanek

e15784

Final report of a phase I/II study of veliparib (Vel) in combination with 5-FU and oxaliplatin (FOLFOX) in patients (pts) with metastatic pancreatic cancer (mPDAC).

Michael J. Pishvaian

4015

Final results of JASPAC05: Phase II trial of neoadjuvant S-1 and concurrent radiotherapy followed by surgery in borderline resectable pancreatic cancer.

Shinichiro Takahashi

4127

Gemcitabine and nab-paclitaxel retreatment as a third-line therapy following second-line FOLFIRINOX for advanced pancreatic adenocarcinoma.

Andrew Peter Dean

e15794

Hereditary cancer genetic testing among patients with pancreatic cancer.

Nassim Taherian

4134

Histology and stage at presentation among patients with rare pancreatic tumors: An exploratory analysis of the SEER database.

Jay Subramoney

e15774

Homologous recombination deficiency (HRD): A biomarker for first-line (1L) platinum in advanced pancreatic ductal adenocarcinoma (PDAC).

Wungki Park

4132

Hospitalization cost and length of stay in pancreatic cancer population: A national inpatient database study.

Ikponmwosa Enofe

e15793

Identifying mechanisms of macrophage-induced metastasis in pancreatic ductal adenocarcinoma.

Tony James Wu

e15705

Immune landscape of neoadjuvant/preoperative chemoradiotherapy in pancreatic cancer.

Kosei Nakajima

e15709

Impact of KRAS mutations in clinical features and survival in pancreatic cancer patients: A single institution experience.

Elizabeth Inga Saavedra

e15779

Impact of no treatment vs other nonsurgical treatments in Pancreatic Adenocarcinoma National Cancer Database: 2004-2014.

Sukamal Saha

e15795

Impact of pretreatment serum creatinine on outcomes in pancreatic adenocarcinoma.

Taha Alrifai

e15749

Improved overall survival (OS) for advanced pancreatic cancer (PDAC) patients (pts) enrolled in the Know Your Tumor (KYT) program whose tumors harbored highly actionable molecular alterations and who received molecularly-matched therapies (tx).

Michael J. Pishvaian

4138

Improving cascade genetic testing for families with inherited pancreatic cancer (PDAC) risk: The genetic education, risk assessment and testing (GENERATE) study.

Matthew B. Yurgelun

TPS4162

Influence of post-resection time to chemotherapy in pancreatic adenocarcinoma on overall survival.

Stephen Abel

e15791

Innate and adaptive immunotherapy: An orchestration of immunogenic cell death by overcoming immune suppression and activating NK and T cell therapy in patients with third line or greater metastatic pancreatic cancer.

Tara Elisabeth Seery

e15787

Main driver genes and BRCA mutation in Chinese patients with pancreatic adenocarcinoma.

Jiangfang Tian

e15741

Metformin use and pancreatic cancer survival in U.S. veterans with diabetes mellitus: Are there racial differences?

Adetunji T. Toriola

4129

Methylated circulating tumor DNA (Met-DNA) as an independent prognostic factor in metastatic pancreatic adenocarcinoma (mPAC) patients.

Daniel Pietrasz

4136

Microbiome signature of bile from pancreatic and biliary tract cancer patients: A pilot study.

Shyam K. Poudel

e15744

Modified FOLFIRINOX as a second-line treatment in pancreatic adenocarcinoma patients with poor performance status.

Adarsh Das

e15796

Mutant KRAS and TP53 with high mutation allelic frequency in ctDNA as poor outcome predictors in metastatic pancreatic cancer.

Shasha Guan

e15763

Nab-paclitaxel plus gemcitabine versus FOLFIRINOX in the first-line chemotherapy for patients with advanced pancreatic ductal adenocarcinoma: A national cohort (Comunica-TTD working group).

Federico Longo

e15707

Nab-paclitaxel/S-1(AS) versus nab-paclitaxel/gemcitabine(AG) for first-line chemotherapy in advanced pancreatic ductal adenocarcinoma (aPDAC): A retrospective analysis of efficacy and safety.

Yuan Zong

e15743

Neoadjuvant FOLFIRINOX versus adjuvant gemcitabine in pancreatic cancer.

Adam R Wolfe

4123

NEONAX trial: Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer, a phase II study of the AIO pancreatic cancer group (AIO-PAK-0313)—Safety interim analysis.

Waldemar Uhl

4128

Niraparib in metastatic pancreatic cancer after previous chemotherapy (NIRA-PANC): A phase 2 trial.

Anup Kasi

TPS4168

Olaparib as maintenance treatment following first-line platinum-based chemotherapy (PBC) in patients (pts) with a germline BRCA mutation and metastatic pancreatic cancer (mPC): Phase III POLO trial.

Hedy L. Kindler

LBA4

PanCO: An open-label, single-arm pilot study of phosphorus-32 (P-32; Oncosil) microparticles in patients with unresectable locally advanced pancreatic adenocarcinoma (LAPC) in combination with FOLFIRINOX or gemcitabine + nab-paclitaxel (GNP) chemotherapies.

Paul J. Ross

4125

Pancreatic cancer survival trends overall, by stage, and histologic sub-type: An analysis of Surveillance, Epidemiology and End Results (SEER) population-based data (2000-2015).

Parisa Karimi

e15772

Pancreatic cancer: Assessment of neoadjuvant chemotherapy outcome based on radiomics of pretreatment computed tomography.

Xiang Li

e15767

Patient and physician preferences for NIH PROMIS patient-reported outcome (PRO) domains in pancreatic ductal adenocarcinoma (PDA).

Michelle Guan

e15721

Phase II multi-institutional study of nivolumab (Nivo), cabiralizumab (Cabira), and stereotactic body radiotherapy (SBRT) for locally advanced unresectable pancreatic cancer (LAUPC).

Deirdre Jill Cohen

TPS4163

Prediction of response to pelareorep plus pembrolizumab in pancreatic ductal adenocarcinoma (PDAC).

Christos Fountzilas

e15726

Predictors of neoadjuvant chemotherapy efficacy in localized pancreatic head cancer: A 15-year experience at a high volume pancreatic cancer center.

Amr I. Al Abbas

e15724

Predictors of post-operative mortality following pancreatectomy: A contemporary nationwide analysis.

Shaakir Hasan

e15706

PRIMUS-002: A multicentre, open-label, phase II study examining FOLFOX and nab-paclitaxel (FA) and nab-paclitaxel and gemcitabine (AG) as neoadjuvant therapy for (borderline) resectable pancreatic cancer (PC), focusing on biomarker and liquid biopsy development.

Derek B. Grose

TPS4166

Profile of somatic mutations in young adults with pancreatic cancer.

Livia Munhoz Rodrigues

e15790

Prognostic factors associated with short-term survival (STS) in advanced pancreatic cancer (APC): A Canadian multicenter analysis from the CHORD Consortium.

Miguel Cardoso

e15717

Prognostic value of lymph node positivity and number of lymph nodes required for accurate staging of pancreatic neuroendocrine tumors.

Jie Hua

e15736

Proton pump inhibitor (PPI) exposure and risk of pancreatic cancer (PC): Meta-analysis.

Nasser Mubarak Al Khushaym

e15755

Randomized phase II study of second-line modified FOLFIRI with PARP inhibitor ABT-888 (Veliparib) (NSC-737664) versus FOLFIRI in metastatic pancreatic cancer (mPC): SWOG S1513.

E. Gabriela Chiorean

4014

Real-world assessment of healthcare costs for patients with metastatic pancreatic cancer following first-line chemotherapy initiation.

Andrea J. Bullock

e15710

Relacorilant (RELA) with nab-paclitaxel (NP): Safety and activity in patients with pancreatic ductal adenocarcinoma (PDAC) and ovarian cancer (OvCA).

Pamela N. Munster

4130

Relapse-free survival (RFS) after surgical resection to predict survival after relapse (SAR) and overall survival (OS) in patients with pancreatic ductal adenocarcinoma (PDA).

Jesus Rodriguez-Pascual

e15735

Relationship between cholangitis, initial chemotherapy regimen, and overall survival in patients with unresectable pancreatic adenocarcinoma.

Melissa Lumish

e15788

Remnant pancreatic volume to predict short-term and long-term outcomes in patients with resected pancreatic cancer.

Ryoichi Miyamoto

e15713

Retrospective determination of the correlation between the distance of tumor manifestation to peripancreatic arteries and overall survival in primary resected pancreatic ductal adenocarcinoma.

Uwe A Wittel

e15745

Rivaroxaban thromboprohylaxis in ambulatory patients with pancreatic cancer: Results from a prespecified subgroup analysis of the CASSINI study.

Saroj Vadhan-Raj

4016

Role of neoadjuvant therapy (NAT) in pancreatic adenocarcinoma (PAC): A single center experience.

Rami Mohamad Nassabein

e15747

Sequential assessments of KRAS-mutated circulating tumor DNA in longitudinal monitoring enable the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.

Fumiaki Watanabe

e15712

Serum microRNA signatures for the detection of pancreatobiliary cancer.

Shuichi Mitsunaga

e15718

Significant neutrophil accumulation, IL-18 deposition, and active inflammasome in tumor regions of human pancreatic ductal adenocarcinoma.

Ahmed Khattab

e15754

SM-88 therapy in high risk poor prognosis pancreatic cancer (PDAC).

Marcus Smith Noel

e15714

SWOG S1505: Initial findings on eligibility and neoadjuvant chemotherapy experience with mFOLFIRINOX versus gemcitabine/nab-paclitaxel for resectable pancreatic adenocarcinoma.

Davendra Sohal

4137

The effect of antibiotic use on survival of patients with resected pancreatic ductal adenocarcinoma.

Merve Hasanov

e15773

The effect of neoadjuvant chemotherapy with gemcitabine and S-1 for resectable pancreatic cancer (randomized phase II/III trial; Prep-02/JSAP-05).

Sohei Satoi

4126

The peritoneal fluid reflects the effect on pancreatic cancer by intraoperative radiation therapy (IORT).

Yun Sun Lee

e15742

The prevalence of hereditary pancreatitis mutations in families with pancreatic cancer.

Rino S. Seedor

e15728

Tolerability and safety of a replication-competent adenovirus-mediated double suicide gene therapy (Ad5-yCD/mutTK(SR39)rep-ADP) with chemotherapy in locally advanced pancreatic cancer: Phase 1 trial.

Jong-Chan Lee

e15761

Transducer array layout optimization for the treatment of pancreatic cancer using Tumor Treating Fields (TTFields) in the phase 3 PANOVA-3 trial.

Ariel Naveh

e15766

Treatment response and survival in patients with pancreatic adenocarcinoma receiving neoadjuvant chemotherapy or chemoradiation.

Ahmed Khattab

e15715

Trends in pancreatic cancer chemotherapy treatment in the United States from 2008 through 2016.

Shirley Hui

e15734

Variation in the surgical management of locally advanced pancreatic cancer.

Bradley Norman Reames

4122